Shareprice
12 Jun 2025

Precision Surgery Improving Outcomes for Cancer Patients

 FluoGuide’s lead product, FG001, lights up cancer and guides surgeons to perform more precise surgeries

New - New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

LatestPress & news

10 Jun 2025 FG001 clinical data in High-Grade Glioma is now published in Neurosurgery News Corporate Information Other Corporate Information mfn-ext-nq mfn-ext-nq-company-announcement English IR
28 May 2025 FluoGuide A/S publishes interim report for the period January – March 2025 - On track - first patients enrolled in CT-005 News English Regulatory Listing Regulation Report Interim Q1 IR

FluoGuideAn introduction

FluoGuide is a biotech company specializing in precision cancer surgery to improve the outcome for patients with cancer.

Clinical studies have confirmed that FG001 is able to light up cancer in patients.

Successful application of FluoGuide’s products has the potential to lower system-wide healthcare costs because it will reduce the recurrence of cancer and lessen general surgical complications. Thereby, patients will require fewer readmissions to hospitals.

Project StatusRapidly progressing pipeline

FluoGuide’s pipeline consists of product candidates that has the potential to light up 80% of solid cancers.

FG001 has successfully completed Phase II trials in aggressive brain cancer and head and neck cancer, demonstrating clinical benefit by lighting up cancerous tissue during surgery.
Additionally, FluoGuide is advancing photosensitizer therapy for brain cancer, aiming to selectively destroy cancer cells while preserving healthy tissue.

We continue to drive innovation to benefit patients, society, and our shareholders.

Pipeline

Pre-clinical
Phase I
Phase II
Phase III
Commercial
FG001
Aggressive brain cancer (FGS)
Info
Next milestone: Consolidated plans
Head & Neck cancer (FGS)
Info
Next milestone: Consolidated plans
Aggressive brain cancer (PTT)
Info
Next milestone: Consolidated plans
Progress

FluoGuideCalendar & events

Full calendar

Latest presentations

All presentations

28 May 2025

Redeye interview on Q1 2025

27 February 2025

Redeye interview on Annual Report 2024

Subscribe for newsletter

Cookies
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings". Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
Save Accept all